Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

59 results about "Retroviral protease inhibitor" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Protease inhibitors are one type of antiretroviral drug used to treat HIV. The goal of these drugs is to reduce the amount of HIV virus in the body (called the viral load) to levels that are undetectable.

Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors

InactiveUS6046190ABiocideOrganic chemistryRetroviral protease inhibitorViral protease

The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.

Owner:GD SEARLE & CO

Resistance-repellent retroviral protease inhibitors

InactiveUS20050267074A1BiocideAntiviralsRetroviral protease inhibitorViral protease

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6172082B1BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Owner:GD SEARLE & CO

Resistance-repellent retroviral protease inhibitors

InactiveUS20050209301A1Prevent slow emergenceSlow emergenceBiocideOrganic chemistryRetroviral protease inhibitorViral protease

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6846954B2Peptide/protein ingredientsOrganic compound preparationProteinase activityRetroviral protease inhibitor

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6924286B1BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Cyclic sulfone containing retroviral protease inhibitors

InactiveUS6875790B2BiocideOrganic chemistryProteinase activityRetroviral protease inhibitor

The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.

Cyclic sulfone containing retroviral protease inhibitors

Cyclic sulfone containing retroviral protease inhibitors

Cyclic sulfone containing retroviral protease inhibitors

Owner:GD SEARLE & CO +1

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS7141609B2BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

InactiveUS6172082B2BiocidePeptide/protein ingredientsProteinase activityRetroviral protease inhibitor

alpha- and beta-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

InactiveUS6861539B1BiocidePeptide/protein ingredientsProteinase activityRetroviral infection

Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Owner:GD SEARLE & CO

Resistance-repellent retroviral protease inhibitors

InactiveUS20060258627A1BiocideOrganic chemistryRetroviral protease inhibitorViral protease

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Resistance-repellent retroviral protease inhibitors

InactiveUS7285566B2BiocidePeptidesRetroviral protease inhibitorMedicine

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Pharmaceutical emulsions for retroviral protease inhibitors

InactiveUS20050276824A1Easy to manageHigh drug loadingBiocideCapsule deliveryEmulsionRetroviral protease inhibitor

The present invention provides an emulsion formulation with high oral bioavailability containing lecithin as an emulsifier and solubilizing agent to achieve a high loading of the pyranone compound of formula I.

Pharmaceutical emulsions for retroviral protease inhibitors

Pharmaceutical emulsions for retroviral protease inhibitors

Pharmaceutical emulsions for retroviral protease inhibitors

Owner:BOEHRINGER INGELHEIM INT GMBH

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

InactiveUS7339078B2BiocidePeptide/protein ingredientsProteinase activityRetroviral infection

Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Owner:GD SEARLE & CO

Benzofuran derived HIV protease inhibitors

InactiveUS7981929B2Improved pharmacokinetic propertiesBiocideOrganic chemistryProteinase activityRetroviral protease inhibitor

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Benzofuran derived HIV protease inhibitors

Benzofuran derived HIV protease inhibitors

Benzofuran derived HIV protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Resistance-repellent retroviral protease inhibitors

InactiveUS20050107342A1BiocidePhosphorous compound active ingredientsRetroviral protease inhibitorMedicine

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Method for preparing intermediates useful in synthesis of retroviral protease inhibitors

InactiveUS6974876B2Silicon organic compoundsCarbamic acid derivatives preparationRetroviral protease inhibitorViral protease

A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.

Method for preparing intermediates useful in synthesis of retroviral protease inhibitors

Method for preparing intermediates useful in synthesis of retroviral protease inhibitors

Method for preparing intermediates useful in synthesis of retroviral protease inhibitors

Owner:GD SEARLE & CO

Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors

InactiveUS7091219B2BiocideOrganic chemistryProteinase activityRetroviral protease inhibitor

Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula:

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.

Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors

Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors

Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors

Owner:GD SEARLE & CO

Resistance-repellent retroviral protease inhibitors

InactiveUS7807845B2BiocideOrganic chemistryRetroviral protease inhibitorViral protease

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Resistance-repellent retroviral protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Retroviral protease inhibitors

InactiveUS7026333B1BiocideOrganic chemistryProteinase activityRetroviral protease inhibitor

HIV protease inhibitors are disclosed which are characterized as having both hydroxyethylamine and N-heterocyclic moieties.

Retroviral protease inhibitors

Retroviral protease inhibitors

Retroviral protease inhibitors

Owner:GD SEARLE & CO

Antiviral medicine and medicine composition thereof

InactiveCN104628771ASignificant pharmaceutical significanceImprove securityOrganic active ingredientsComponent separationChemical structureAntiviral drug

The invention relates to an antiviral medicine and a medicine composition thereof, in particular relates to an anti-human immunodeficiency virus (HIV) medicine and a medicine composition thereof, and especially relates to a medicine which can be taken as a retrovirus protease inhibitor. The retrovirus protease inhibitor has a chemical structure shown in a formula I.

Antiviral medicine and medicine composition thereof

Antiviral medicine and medicine composition thereof

Antiviral medicine and medicine composition thereof

Owner:HESI XIAN BIOTECH

Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

InactiveUS20070004646A1BiocidePeptide/protein ingredientsProteinase activityRetroviral infection

Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Owner:RICOH KK

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

InactiveUS7045518B2BiocideOrganic chemistryProteinase activityRetroviral protease inhibitor

Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

Owner:GD SEARLE & CO

Combination therapy for treatment of FIV infection

InactiveUS6875773B1BiocideOrganic chemistryRetroviral protease inhibitorMedicine

The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor.

Combination therapy for treatment of FIV infection

Combination therapy for treatment of FIV infection

Combination therapy for treatment of FIV infection

Owner:DUNN BEN M +2

Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound.

InactiveCN1980907AOrganic chemistryAntiviralsProteinase activityRetroviral protease inhibitor

The present invention describes a new one ritonavir analogous compound that presents significantly superior activity in inhibition of HIV protease. There are also described the usage of the ritonavir analogous compound of the present invention or salt, ester or prodrug thereof as well as the usage of the compound and its pharmaceutical compositions in medicine, particularly, in the treatment of HIV infection, by itself or in combination with others anti-HIV drugs.

Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound.

Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound.

Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound.

Owner:CRISTALIA PROD QUI FARM LTDA

Cyclic sulfone containing retroviral protease inhibitors

InactiveUS20050119257A1BiocideOrganic chemistryProteinase activityRetroviral protease inhibitor

The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.

Cyclic sulfone containing retroviral protease inhibitors

Cyclic sulfone containing retroviral protease inhibitors

Cyclic sulfone containing retroviral protease inhibitors

Owner:GD SEARLE & CO +1

Method of preparing retroviral protease inhibitor intermediates

InactiveUS6849760B2Increase synthesisGroup 4/14 element organic compoundsOrganic compound preparationOrganic acidRetroviral protease inhibitor

Chiral hydroxyethylamine, hydroxyethylurea or hydroxyethylsulfonamide isostere containing retroviral protease and renin inhibitors can be prepared by multi-step syntheses that utilize key chiral amine intermediates. This invention is a cost effective method of obtaining such key chiral amine intermediates enantiomerically, diastereomerically and chemically pure. The method is suitable for large scale (multikilogram) productions. This invention also encompasses organic acid and inorganic acid salts of the amine intermediates.

Method of preparing retroviral protease inhibitor intermediates

Method of preparing retroviral protease inhibitor intermediates

Method of preparing retroviral protease inhibitor intermediates

Owner:GD SEARLE & CO

Benzofuran derived HIV protease inhibitors

InactiveUS20080227744A1Improved pharmacokinetic propertiesBiocideOrganic chemistryProteinase activityRetroviral protease inhibitor

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Benzofuran derived HIV protease inhibitors

Benzofuran derived HIV protease inhibitors

Benzofuran derived HIV protease inhibitors

Owner:SEQUOIA PHARMACEUTICALS INC

Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

InactiveUS6951886B2BiocideOrganic chemistryUrea derivativesProteinase activity

Succinoylamino hydroxyethylamino sulfonyl urea derivatives of the formula: wherein the substituents are as defined in the specification, are effective as retroviral protease inhibitors and in particular as inhibitors of HIV protease.

Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

Owner:GD SEARLE & CO

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

InactiveUS20060264483A1BiocideOrganic chemistryProteinase activityRetroviral infection

Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors

Owner:GD SEARLE & CO

Popular searches

Virus inhibitors Enzyme inhibitor Human immuno deficiency virus Proteases Sulfonosine Molecular biology Sulfonilamide Amide Biochemistry Human immunodeficiency virus (HIV)

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap